We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.
- Authors
Coulter, Jonathan B.; Easwaran, Hariharan
- Abstract
Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies. Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways involving EZH2 and HDACs. This Primer explores a PLOS Biology study showing that combined epigenetic therapy targeting these enzymes can activate cellular stress pathways, which may sensitize CRPC to both epigenetic and standard therapies.
- Subjects
CASTRATION-resistant prostate cancer; ANDROGEN receptors; DEACETYLASES; KINASE inhibitors
- Publication
PLoS Biology, 2023, Vol 21, Issue 4, p1
- ISSN
1544-9173
- Publication type
Article
- DOI
10.1371/journal.pbio.3002081